Quick Facts
Plain-English Summary
Tirzepatide is a synthetic 39-amino-acid peptide engineered to co-activate the GIP receptor and GLP-1 receptor simultaneously. This dual agonism appears synergistic: the GIPR component amplifies the GLP-1-mediated weight loss and glycemic effects beyond what GLP-1 agonism alone achieves. It is structurally based on the endogenous GIP hormone sequence, with fatty acid conjugation for extended half-life.
The SURPASS clinical trial series (phases I–V) enrolled more than 10,000 participants with type 2 diabetes. In SURPASS-2, a head-to-head RCT vs semaglutide 1mg (n=1,879), tirzepatide 15mg produced significantly greater reductions in HbA1c (−2.46% vs −1.86%) and body weight (−12.4 kg vs −6.2 kg). This is one of the few direct comparisons in this drug class.
For obesity without diabetes, the SURMOUNT-1 trial (n=2,539) demonstrated mean weight loss of 20.9% at maximum dose (15mg) vs 3.1% for placebo — the largest weight loss ever reported in a pharmacological obesity trial. Approximately 1 in 3 patients lost ≥25% of body weight.
The compound is FDA-approved — an important distinction from all other compounds in this database. Branded versions (Mounjaro, Zepbound) are manufactured under pharmaceutical GMP standards. Compounded tirzepatide from pharmacies lacks this guarantee and the FDA has raised safety concerns about compounded versions.
Compounded tirzepatide is not equivalent to FDA-approved branded products. Purity, potency, and formulation may differ significantly. The FDA has explicitly warned against use of compounded tirzepatide from compounding pharmacies without medical supervision. All trial data supporting this compound was generated with the branded, GMP-manufactured formulation.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Obese mice — diet-induced obesity | Tirzepatide reduced body weight by 40% more than GLP-1 agonist alone in matched dose groups; metabolic improvements in liver fat, triglycerides, and insulin sensitivity were significantly greater with dual agonism. | Preclinical |
| Non-human primate — metabolic model | Weight loss of 11% vs 2% for GLP-1 agonist alone; confirmed GIPR synergy in a closer translational model. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| SURPASS-2 (NEJM 2021) | T2D adults (n=1,879) | — | RCT |
| SURMOUNT-1 (NEJM 2022) | Obese adults without T2D (n=2,539) | — | RCT |
| SURPASS-CVOT | High CV risk T2D (ongoing) | — | Ongoing |
TIRZEPATIDE has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
Generally well tolerated in RCTs. Most common adverse events are gastrointestinal (nausea, vomiting, diarrhea) and are dose-dependent, transient, and most frequent during dose escalation. Serious adverse events were comparable to placebo in trials. A small increase in heart rate (~2 bpm) was noted.
Thyroid C-cell tumor signal was observed in rodents at high doses (class effect of GLP-1RAs). FDA mandates a black-box warning. Risk in humans is unknown but considered low based on mechanistic differences. Acute pancreatitis is a rare but reported association with the GLP-1RA class.
- Nausea (common, usually transient)
- Vomiting — dose-related
- Diarrhea or constipation
- Reduced appetite (intended but can cause inadequate nutrition)
- Injection site reactions
- Personal or family history of MTC or MEN2 (class thyroid warning)
- Pancreatitis history
- Severe GI disease
- Pregnancy (category X — stop before conception)
- Children under 18 (not studied)
TIRZEPATIDE is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of TIRZEPATIDE for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
I prescribe Mounjaro and the results in the right patients are genuinely remarkable. The GIP dual action is real — patients lose more weight than on semaglutide at comparable doses. The supply issues have been a nightmare though and the compounded versions make me nervous.
12 weeks in on tirzepatide. Down 18 lbs. The nausea weeks 1–4 was rough but manageable. By week 6 I had basically no appetite for the first time in my adult life. Working with a physician, getting labs every 8 weeks.
If you're getting this from a compounding pharmacy without a legit script and real medical supervision, you're taking a risk. Not just legal — the purity testing on compound tir varies wildly. The SURMOUNT data was done on Lilly's product with their formulation. You're not getting that from a random pharmacy.
People keep claiming 22% weight loss like everyone achieves it. That's the maximum dose average. Many people get 10-15%. Still remarkable but manage expectations. Also the weight comes back when you stop — this is lifelong management, not a cure.